Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma

被引：3

作者：

Tang, Quanqing ^{[1
]}

Li, Shihao ^{[1
]}

Huang, Gaozhen ^{[1
]}

Liu, Hongwei ^{[1
]}

机构：

[1] Guangdong Med Univ, Dept Urol, Affiliated Hosp, Zhanjiang, Guangdong, Peoples R China

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2023年 / 119卷

关键词：

Metastatic urothelial carcinoma; Immune checkpoint inhibitor; Programmed death-1; Programmed death-ligand 1; Immunotherapy; CISPLATIN-INELIGIBLE PATIENTS; IMMUNE CHECKPOINT INHIBITORS; OPEN-LABEL; SINGLE-ARM; CLINICAL ACTIVITY; GENE-EXPRESSION; ADVERSE EVENTS; CANCER; MULTICENTER; PEMBROLIZUMAB;

D O I：

10.1016/j.intimp.2023.110158

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Urothelial carcinoma (UC) is a very common malignant tumor. In the past few decades, platinum-based chemotherapy has been regarded as the standard recommended regimen for patients with metastatic urothe-lial carcinoma (mUC) who can receive either cisplatin or carboplatin. The emergence of immune checkpoint inhibitors (ICIs) brought some hope for possible treatments for mUC patients who were unfit for platinum therapy. ICIs drugs have emerged as new potential weapons to overcome UC in our lifetime. ICIs block the binding of programmed death-1 (PD-1) to programmed death-ligand 1 (PD-L1), leading to enhancement of the immune function of antitumor T cells. In the treatment of UC, ICIs show an apparent ascendancy and effectively enhance survival rates. With good tolerability and remarkable effects, ICIs have given thousands of patients hope. This article mainly shows the application of PD-1 and PD-L1 inhibitors in mUC.

引用

页数：8

共 65 条

[1] Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? [J].

Apetoh, L. ;

Ladoire, S. ;

Coukos, G. ;

Ghiringhelli, F. .

ANNALS OF ONCOLOGY, 2015, 26 (09) :1813-1823

[2] Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis [J].

Apolo, Andrea B. ;

Ellerton, John A. ;

Infante, Jeffrey R. ;

Agrawal, Manish ;

Gordon, Michael S. ;

Aljumaily, Raid ;

Gourdin, Theodore ;

Dirix, Luc ;

Lee, Keun-Wook ;

Taylor, Matthew H. ;

Schoeffski, Patrick ;

Wang, Ding ;

Ravaud, Alain ;

Manitz, Juliane ;

Pennock, Gregory ;

Ruisi, Mary ;

Gulley, James L. ;

Patel, Manish R. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[3] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

[4]

Balar A.V., 2022, ANN ONCOL, V34, P289, DOI [10.1016/j.annonc.2022.11, DOI 10.1016/J.ANNONC.2022.11.012]

[5] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[6] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[7] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[8] New Therapeutic Challenges in Advanced Bladder Cancer [J].

Bellmunt, Joaquim ;

Petrylak, Daniel P. .

SEMINARS IN ONCOLOGY, 2012, 39 (05) :598-607

[9] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition [J].

Buchbinder, Elizabeth I. ;

Desai, Anupam .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01) :98-106

[10] Oncology Meets Immunology: The Cancer-Immunity Cycle [J].

Chen, Daniel S. ;

Mellman, Ira .

IMMUNITY, 2013, 39 (01) :1-10

← 1 2 3 4 5 6 7 →